Melbourne, FL and Charleston, SC
Alertgy, a leader in 100% non-invasive, continuous glucose monitoring (CGM) technology announced today the appointment of Mark Semler as its new CEO. Mr. Semler brings over 20 years of experience in the medical device industry as an executive, R&D leader, and engineer. Before joining Alertgy, he was CEO of ZIAN, a technology accelerator for the Medical University of South Carolina, where his team selected innovative technologies, got funding, developed them, and licensed them to industry. Before ZIAN, Mark was the VP of R&D for Orthofix’s $140M spinal implants division, leading a 30-member team of engineers and designers in the end-to-end development and commercialization of dozens of novel spinal implant systems. Mr. Semler began his career at Boston Acoustics before transitioning to medical devices.
Mark Semler stated: “I am honored to be a part of the Alertgy mission. What Marc Rippen and his team have created over the last five years has the potential to make a big impact on the world.
This is an amazing technology, and the company has been extremely efficient with capital. Their progress on each generation of the technology has put us in a good position to move this through development and into clinical trials. We will be moving into a new phase and I look forward to working with and growing the team.”
Mr. Marc Rippen, founder, chairman of the board and outgoing CEO stated: “We are thrilled to welcome Mark. His multifaceted background will be instrumental in taking Alertgy to the next phase of medical device development and commercialization. His strong industry network will help complete the current and initiate future rounds of funding as well as onboard new industry talent in key financial, quality, regulatory, marketing and engineering areas. I look forward to working with Mark and making DeepGluco™ a reality for hundreds of millions of diabetic patients and individuals with borderline diabetes, which may grow into the billions worldwide.”
Mr. Rippen will continue to chair Alertgy’s board, and as Chief Innovation Officer will focus on completing the current generation device for continued clinical testing.
About Alertgy: Alertgy is a pioneer in 100% non-invasive continuous blood glucose monitoring (CGM) technology. Using a patented radio frequency sensor, Alertgy’s DeepGluco™R&D is currently validating a wearable device with the goal that it will accurately measure blood glucose in real time, up to 3 times per minute. Most importantly, using a proprietary AI algorithm, DeepGluco™ strives to provide invaluable, up to the minute life-saving alerts to patients, their families, and designated HCPs. Unlike other CGMs, DeepGluco™’s noninvasive design hopes to eliminate interstitial lag and avoid the painful and uncomfortable side effects of expensive and invasive patches, needles, and implants. The final DeepGluco™ form factor will be a modern smart watch, available to consumers following FDA and CE approvals.
For more information please contact:
Director of Marketing Strategy